Research is being conducted on the metabolic reprogramming of myeloid cells in cancer, including the lactate-NAMPT axis. This area of study has implications for therapeutics, with some approaches involving ai-guided therapies and targeting the metabolic-epigenetic-immune axis. The research spans various types of cancer, including acute myeloid leukemia and renal cell carcinoma, and explores the role of enzymes such as NAMPT in inflammation and tumor development.